Provided by Tiger Trade Technology Pte. Ltd.

Harrow Health Inc

37.55
-0.3000-0.79%
Volume:354.69K
Turnover:13.37M
Market Cap:1.41B
PE:-37.58
High:38.00
Open:37.92
Low:37.40
Close:37.85
52wk High:54.85
52wk Low:28.54
Shares:37.49M
Float Shares:28.93M
Volume Ratio:0.87
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9993
EPS(LYR):-0.1400
ROE:-116.07%
ROA:-0.45%
PB:92.61
PE(LYR):-268.21

Loading ...

Harrow Among 3 Prime Growth Stocks With Significant Insider Ownership

Simply Wall St.
·
Jul 17

Craig-Hallum Sticks to Its Buy Rating for Harrow Health (HROW)

TIPRANKS
·
Jul 13

Harrow (HROW) Could Be 38% Undervalued Following BYOOVIZ Launch

Simply Wall St.
·
Jul 03

Analysts Are Bullish on These Healthcare Stocks: Plus Therapeutics (PSTV), Harrow Health (HROW)

TIPRANKS
·
Jul 01

Harrow Expands Retina Portfolio With US Launch of Byooviz

MT Newswires Live
·
Jul 01

Harrow announces commercial launch of Byooviz in the U.S.

TIPRANKS
·
Jul 01

Samsung Bioepis Relaunches Byooviz® (ranibizumab-nuna) in the United States in Partnership with Harrow

THOMSON REUTERS
·
Jul 01

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

GlobeNewswire
·
Jul 01

Harrow holds annual shareholder meeting, elects four directors

Reuters
·
Jun 22

Harrow (HROW) Stock After VERKAZIA Relaunch A Fresh Look At The Valuation Gap

Simply Wall St.
·
Jun 12

What Harrow (HROW)'s VERKAZIA Re‑Launch in Pediatric VKC Means For Shareholders

Simply Wall St.
·
Jun 11

Harrow Shares Rise on Relaunch of Pediatric Eye Disease Treatment

Dow Jones
·
Jun 10

Harrow Relaunches Verkazia for Vernal Keratoconjunctivitis

MT Newswires Live
·
Jun 10

Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

THOMSON REUTERS
·
Jun 10

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS)

TIPRANKS
·
Jun 10

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 04

Harrow (HROW) Is Up 6.8% After Reaffirming 2026 Revenue Outlook Despite Wider Q1 Losses - What's Changed

Simply Wall St.
·
May 26

Harrow director Adrienne Graves acquires 1,000 common shares for $31,070

Reuters
·
May 19

Harrow director Lauren Silvernail acquires $31,000 in common shares

Reuters
·
May 19

Harrow CEO buys $302K, CFO buys $104.7K in common stock

TIPRANKS
·
May 15